key: cord-0892172-cuz7vrds
authors: Mobayen, Golzar; Dhutia, Amrita; Clarke, Candice; Prendecki, Maria; McAdoo, Stephen; Keniyopoullos, Renos; Malik, Talat; Laffan, Michael; Willicombe, Michelle; McKinnon, Thomas
title: Severe COVID‐19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis
date: 2021-09-12
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12582
sha: 615acd7f7ecbbca351f0b44b50ab43677fa90f2f
doc_id: 892172
cord_uid: cuz7vrds

BACKGROUND: A major clinical feature of severe coronavirus diease 2019 (COVID‐19) is microvascular thrombosis linked to endothelial cell activation. Consistent with this, a number of studies have shown that patients with severe COVID‐19 have highly elevated plasma levels of von Willebrand Factor (VWF) that may contribute to the prothrombotic phenotype. In the current study, we investigated the extent of endothelial activation in patients receiving hemodialysis who had either mild or severe COVID‐19. METHODS: Plasma VWF, ADAMTS‐13, angiopoietin‐2 (Ang2), and syndecan‐1 levels were determined by ELISA. The sialic acid content of VWF was investigated using a modified ELISA to measure elderberry bark lectin, specific for sialic acid residues, binding to VWF. RESULTS: Patients receiving hemodialysis with severe COVID‐19 had significantly higher plasma levels of VWF and lower ADAMTS‐13. VWF levels peaked and were sustained during the first 10 days after positive confirmation of infection. While Ang2 trended toward being higher in severely ill patients, this did not reach significance; however, severely ill patients had significantly higher soluble syndecan‐1 levels, with high levels related to risk of death. Finally, higher VWF levels in severely ill patients were correlated with lower VWF sialic acid content. CONCLUSIONS: Severe COVID‐19 in patients undergoing hemodialysis is associated with both acute and sustained activation of the endothelium, leading to alteration of the VWF/ADAMTS‐13 axis. Lower VWF sialic acid content represents altered VWF processing and further confirms the disturbance caused to the endothelium in COVID‐19.

• Severe coronavirus disease 2019 (COVID-19) is associated with a risk of thrombosis.

• We investigated markers of endothelial activation in patients with COVID-19 undergoing hemodialysis.

• Severe COVID-19 was associated with elevated von Willebrand factor (VWF) and soluble syndecan-1 and decreased ADAMTS-13.

• VWF sialic acid content was significantly decreased in severe COVID-19.

Since its emergence in late 2019, coronavirus disease 2019 has become a worldwide pandemic with over 117 million cases worldwide and an overall mortality rate of 2% as of March 2021. The causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects cells via interaction of its Spike protein with the angiotensin-converting enzyme 2 (ACE2) receptor. 1 Although many infected individuals remain asymptomatic or only experience mild symptoms, ≈15% of infected patients develop severe disease characterized by respiratory distress and a cytokine storm. 2 Another emerging feature of severe COVID-19 is excessive endothelial activation leading to profound alterations in blood coagulation that result in venous and arterial thrombosis in the lungs and other organs. [3] [4] [5] [6] Recent work has demonstrated that SARS-Cov-2 is unlikely to directly infect the endothelium due to lack of ACE2 expression on endothelial cells 7 and thus the endothelial damage and activation is likely caused by the associated cytokine storm and circulating platelet, immune cells, and complement activation.

Von Willebrand factor (VWF) is ubiquitously expressed throughout the endothelium and plays a major role in hemostasis by capturing platelets to sites of vessel damage and is characterized by its large multimeric structure that is essential to its hemostatic function. 8 Within endothelial cells VWF is stored in Webiel-Palade bodies along with a series of proteins involved in angiogenesis, inflammation, and thrombosis. 9 The multimeric size of VWF is controlled by the enzyme ADAMTS-13 that cleaves VWF in its A2 domain, reducing its multimeric size and platelet capture potential. 10 A growing body of evidence has implicated the VWF-ADAMTS-13 axis as playing a major role in the pathogenesis of severe COVID-19. [11] [12] [13] [14] [15] [16] [17] There is now clear evidence that in severe COVID-19 infection plasma VWF levels can be highly elevated with a corresponding decrease in ADAMT-13 levels and activity. In this report, we describe highly elevated VWF and lower ADAMTS-13 levels in patients receiving in-center hemodialysis with severe COVID-19 compared to hemodialysis patients without COVID-19, and show that extreme VWF levels are associated with an alteration in its glycosylation pattern.

Citrate anticoagulated plasma was obtained from patients receiving for severe disease (respiratory rate ≥30/min, blood oxygen saturation ≤90%, arterial oxygen partial pressure:fractional inspired oxygen ratio <300, or infiltrates affecting 50% of the lung field within 24-48 hours).

Von Willebrand factor levels were determined by an "in-house" ELISA as previously described. 18 ADAMTS-13, angiopoitein-2 (Ang2) and syndecan-1 levels were determined by ELISAs all purchased from R&D Systems (Minneapolis, MN, USA) and all carried out according to the manufacturer's protocol. Binding of elderberry bark lectin (EBL), specific for terminal sialic acid residues, to VWF was performed using a modified VWF ELISA essentially as previously described. 19 Statistical analysis was performed using Prism version 9 (GraphPad Software, La Jolla, CA, USA).

Thirty-nine patients receiving HDx with confirmed symptomatic COVID-19 were recruited. Fifteen patients were classified as having mild COVID, 24 had severe COVID, and 10 patients were COVID negative. Patient demographics and characteristics are shown in Table 1 . There were no notable differences between the demographics and clinical status of the COVID-19-positive and -negative groups. Serial samples were obtained for patients with mild and severe disease. Twenty-five percent of the patients (n = 6) with severe COVID died. D-dimer and hemoglobin levels and platelet counts were obtained for the mild and severe cases. In keeping with previous reports, hemoglobin levels were significantly lower in severe COVID cases compared to mild disease ( Figure 1A ). 20 Platelet counts did not differ between severe and mild cases ( Figure 1B) , and although no significant difference in D-dimer levels was seen between disease severities ( Figure 1C ), both groups of mild and severe patients had D-dimer levels above the upper limit of normal (250 ng/mL). However, this may be attributed to the chronic kidney disease status of these patients rather COVID-19, especially with the mild patients.

Since VWF is elevated in severe COVID-19, we compared peak plasma VWF levels between groups. No significant differences in VWF levels were observed between control patients median (in- In light of the high and in some cases extreme levels of VWF observed in this study, we hypothesized that biosynthesis of VWF may be altered. VWF undergoes extensive glycosylation with many of its N-and O-linked glycan chains capped with terminal sialic acid residues. 25 A modified ELISA measuring the binding of EBL to VWF was used to measure the sialic acid status of VWF.

The control and mild COVID-19 groups both demonstrated similar EBL binding: 124% (91-150) and 112% (88-162), respectively.

Interestingly, patients with severe COVID-19 had significantly less sialic acid present on their VWF (66%; 44-87) ( Figure 2F ). There was a significant inverse correlation between VWF levels and EBL binding, demonstrating that high VWF levels were associated with lower sialic acid content ( Figure 2G ). The significance of this is unknown; however, we have previously shown that VWF lacking sialic acid is less susceptible to ADAMTS-13 proteolysis, and previous reports also demonstrate that VWF devoid of sialic acid has increased reactivity toward platelets. 26 Ang2 is stored alongside VWF and has been shown to be a marker of severe COVID-19. 29 In this study, plasma Ang2 levels were not statistically different between the controls and mild and severe COVID-19 cases, although there was a trend toward higher Ang2 levels in patients with severe COVID. Finally, we measured plasma levels of syndecan-1, which has been previously shown to be a marker of endothelial damage. 30 Plasma syndecan-1 levels were higher in se- 

This study allowed direct comparison between mild and severe COVID-19 cases. The findings from this study confirm that during severe COVID-19 infection the endothelium is severely disrupted, resulting in release of VWF and subsequent consumption of ADAMTS-13, which has the potential to lead to a thrombotic phenotype, although the prophylactic anticoagulation given to our patient cohort may have prevented this and adds support to the use of anticoagulants in the treatment of COVID-19.

Our observations that the sialic acid content of VWF in severe COVID-19 is altered, raises a new avenue for investigation, and will be of interest to see if this phenomenon is observed in other patient cohorts. 

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Severe covid-19 pneumonia: pathogenesis and clinical management

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Prognostic value of fibrinogen among COVID-19 patients admitted to an emergency department: an Italian cohort study

Venous thromboembolism and its association with COVID-19: still an open debate

Lack of evidence of angiotensinconverting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells

Biochemistry and genetics of von Willebrand factor

Functional architecture of Weibel-Palade bodies

Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis

Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients

Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2

Cardiac dysfunction and thrombocytopenia-associated multiple organ failure inflammation phenotype in a severe paediatric case of COVID-19

Reduction of ADAMTS13 levels predicts mortality in SARS-CoV-2 patients

The ADAMTS13-von Willebrand factor axis in COVID-19 patients

Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation

Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality

N-linked glycosylation of VWF modulates its interaction with ADAMTS13

Increased galactose expression and enhanced clearance in patients with low von Willebrand factor

Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia

An inflammatory cytokine signature predicts COVID-19 severity and survival

Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Amino acid sequence of human von Willebrand factor

Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13

O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions

Decreased sialic acid content of plasma von Willebrand factor in precapillary pulmonary hypertension

Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19

Possible involvement of syndecan-1 in the state of COVID-19 related to endothelial injury

Severe COVID-19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis

GM performed experiments, analyzed data, and wrote the paper. AD collected data and wrote the paper. CC, MP, and SM collected samples, analyzed data, and wrote the paper. RK performed experiments, T Malik collected samples, and MW analyzed data and wrote the paper. TMcKinnon performed experiments, analyzed data, and wrote the paper.

The authors declare no conflicts of interest.

Candice Clarke @clclarke227

Stephen McAdoo @stephenmcadooMichelle Willicombe @mkwillicombe